Verzenio

Save as Favorite
Sign in to receive recommendations (Learn more)

Verzenio (chemical name: abemaciclib) was approved by the U.S. Food and Drug Administration (FDA) on Sept. 28, 2017 to be used in combination with Faslodex (chemical name: fulvestrant) to treat women diagnosed with hormone-receptor-positive, HER2-negative metastatic or advanced-stage breast cancer if the cancer progressed after hormonal therapy treatment.

Verzenio also was approved to be used alone to treat women and men diagnosed with hormone-receptor-positive, HER2-negative metastatic or advanced-stage breast cancer if the cancer progressed after hormonal therapy treatment and earlier chemotherapy for metastatic disease.

On Feb. 26, 2018, the FDA approved Verzenio to be used in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic or advanced-stage hormone-receptor-positive, HER2-negative breast cancer that has not been treated with hormonal therapy yet.

Verzenio is a pill taken by mouth. The recommended starting doses of Verzenio are 150 mg twice per day in combination with Faslodex or 200 mg twice per day used alone.

In this section you can learn more about:


Was this article helpful? Yes / No

Internal miniad kcc
Back to Top